technology Essays

552 Words3 Pages
THURSDAY, July 21 (HealthDay News) -- Following surgery, a single dose of the cancer drug carboplatin is just as effective, and less toxic, than the standard three weeks of radiation therapy traditionally used to fight stage 1 seminoma, a form of testicular cancer, British researchers report. In addition, treatment with carboplatin results in the development of fewer new seminomas compared with traditional radiation therapy, according to the report in the July 23 issue of The Lancet. For the past half-century, the standard care for seminoma has been to remove the cancerous testicle, usually followed by three weeks of radiotherapy. However, the researchers point to previous studies that found that patients followed for up to 30 years…show more content…
"We also found a very exciting effect," Oliver added. "For patients treated with carboplatin, there are 72 percent less tumors of the same sort in the other testis compared with radiation treatment," he said, meaning that "we may be able to reduce the necessity of taking the whole testicle." The advantage of carboplatin treatment is that it is quick, effective and less toxic compared with radiation. "It means one day as an outpatient for a short drip in the arm," Oliver said. "You go home and sleep it off over the weekend and can be back to work after that, whereas with radiation you have to have three weeks of treatments." Experts think the findings may turn carboplatin treatment into a viable new option for testicular cancer patients. "Traditionally, radiation has been used, and it's a long haul. And it has some major side effects," said Dr. Herman Kattlove, a medical oncologist and spokesman for the American Cancer Society. "A single dose of carboplatin is pretty easy. They give that to 80-year-olds," he added. "If I were in practice I would definitely use this approach," Kattlove said. The three-year study follow-up used to track the recurrence of seminoma is a little short, cautioned Dr. Philip Kantoff, a professor of oncology at Dana-Farber Cancer
Open Document